---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-286862"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:23:33.190910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke presents STK-001 data at AES 2023: seizure reductions and cognition gains in Dravet syndrome

## Summary
- Higher STK-001 brain exposure linked to greater seizure reductions in 72 patients (R=-0.23, P<0.001).
- Multiple 70mg doses of STK-001 showed the largest reductions in convulsive seizure frequency.
- 90% of Phase 1/2a completers enrolled in open-label extension studies (SWALLOWTAIL & LONGWING).
- BUTTERFLY natural history study: patients on ~3.5 anti-seizure drugs saw no meaningful seizure improvement over 2 years.
- OLE data showed substantial improvements in cognition and behavior over 12 months, supporting disease modification.

## SEC filing metadata
- accession: 0001193125-23-286862
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312523286862/0001193125-23-286862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312523286862/d619524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-286862
- JSON: https://secwatch.observer/filing/0001193125-23-286862.json
- Plain text: https://secwatch.observer/filing/0001193125-23-286862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.